Clinical-stage biotech developing off-the-shelf neoantigen cancer immunotherapies
Nouscom is a Basel-based clinical-stage biotech founded in 2015 that develops next-generation neoantigen-targeted immunotherapies, with a focus on cancer interception. Its lead programme NOUS-209 is an investigational off-the-shelf neoantigen-based immunotherapy for people with Lynch Syndrome. Marina Udier is CEO. In October 2026 it closed an oversubscribed 120 million euro Series D co-led by M Ventures and Revelation Partners, with new investors Angelini Ventures, the EIB and Neva SGR and existing investors including 5AM Ventures, Versant Ventures and EQT Life Sciences.
For people
For agents
Nothing listed yet.